Hemostatic powder for rapid hemostasis of traumatic hemorrhage and preparation method and application thereof

Through the combination of sodium alginate, CaCl2, Ce(NO3)3·6H2O and graphene oxide, a high viscosity and high mechanical strength hemostatic gel is formed, which solves the poor effect of existing hemostatic materials in severe jet bleeding of the large artery. The problem has achieved rapid and effective hemostasis effect, and the materials are environmentally friendly and easy to degrade, and are suitable for pre-hospital first aid and battlefield first aid.

CN119015480APending Publication Date: 2024-11-26SHANGHAI PUDONG NEW AREA PEOPLES HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411145240.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing hemostatic materials are not effective in the face of severe jet-like bleeding from the major arteries and are expensive. The domestic market lacks suitable rapid hemostatic materials, resulting in high mortality rates caused by uncontrollable bleeding on the battlefield.

Method used

Develop a hemostatic powder containing sodium alginate, CaCl2 and Ce(NO3)3·6H2O, and form a high viscosity and high mechanical strength gel through the absorption of water and the coordination of sodium alginate to become viscous and cerium ions, combining with graphite oxide Ethylene crosslinking forms a dense mesh structure to promote platelet coagulation and block bleeding.

Benefits of technology

It achieves rapid and effective platelet coagulation and bleeding site sealing, improves the control effect of major bleeding, reduces mortality, and is derived from natural biological products, is easy to degrade, is environmentally friendly, and is easy to prepare.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015480A_ABST
    Figure CN119015480A_ABST
Patent Text Reader

Abstract

The invention discloses styptic powder for rapid hemostasis of traumatic bleeding as well as a preparation method and application of the styptic powder. The styptic powder disclosed by the invention is prepared from sodium alginate, CaCl2 and Ce (NO3) 3.6 H2O. The prepared styptic powder can absorb water to generate a cross-linking reaction, hydrogel is formed on a wound surface in situ, a hyperbranched network structure is formed, and the styptic powder has good water absorption capacity and mechanical performance and has good clinical application and transformation potential in the aspect of pre-hospital rapid hemostasis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of hemostatic materials, in particular to a hemostatic powder used for rapid hemostasis of traumatic hemorrhage, and a preparation method and application thereof. Background Art

[0002] Traumatic massive bleeding is one of the main causes of shock and death, especially in accidents such as car accidents and natural disasters. The total amount of blood in the human body is relatively constant. Once it is excessively reduced, it will quickly cause multiple complications, and in severe cases, it can lead to death. Statistics show that in accidents, the number of deaths due to massive bleeding accounts for as high as 39%, and on the battlefield, the mortality rate caused by uncontrollable bleeding is more than 85%. Studies have shown that about 2.5% of deaths can be avoided by taking hemostatic drugs or interventional treatments in the early stages of uncontrollable bleeding.

[0003] Rapid hemostasis can improve the survival rate of the injured in first aid, especially pre-hospital first aid. Pre-hospital first aid is usually the first aid for the injured caused by an accident before receiving professional medical treatment.

[0004] At present, the commonly used hemostatic materials in clinical practice, such as Merocel and Ivalon, are mainly suitable for hemostasis in daily surgery, but the hemostasis effect for severe jet-like bleeding from aorta is not ideal. These materials are often expensive and most of them rely on imports, so there is a gap in the domestic market in this field.

[0005] In summary, the development of rapid hemostatic materials and related products for trauma hemostasis and emergency rescue has always been a hot topic of research at home and abroad. Bleeding control is an important technical problem in military and civilian trauma centers around the world. Summary of the invention

[0006] The purpose of the present invention is to develop a new, effective and reasonably priced rapid hemostatic material to meet the needs of pre-hospital emergency and battlefield emergency. This material should be able to quickly control heavy bleeding and improve the survival rate of the injured, especially before emergency care arrives.

[0007] In order to achieve the above object, the present invention provides a hemostatic powder for rapid hemostasis of traumatic bleeding, comprising: sodium alginate, CaCl2 and Ce(NO3)3·6H2O.

[0008] Optionally, the mass ratio of sodium alginate:CaCl2:Ce(NO3)3·6H2O is (5-20):1:(1-2).

[0009] Optionally, the mass ratio of sodium alginate:CaCl2:Ce(NO3)3·6H2O is 10:1:1.

[0010] Optionally, the hemostatic powder further comprises: graphene oxide.

[0011] Optionally, the mass ratio of sodium alginate:CaCl2:Ce(NO3)3·6H2O:graphene oxide is (5-20):1:(1-2):(0.1-0.5).

[0012] Optionally, the mass ratio of sodium alginate:CaCl2:Ce(NO3)3·6H2O:graphene oxide is 10:1:1:(0.1-0.5).

[0013] Optionally, the mass ratio of sodium alginate:CaCl2:Ce(NO3)3·6H2O:graphene oxide is 10:1:1:0.3.

[0014] The present invention also provides a method for preparing the hemostatic powder for rapid hemostasis of traumatic hemorrhage, comprising the following steps:

[0015] Step S1, grinding anhydrous calcium chloride particles into anhydrous calcium chloride powder, the powder particle size range is 1 μm-50 μm;

[0016] Step S2, the anhydrous calcium chloride powder is evenly mixed with sodium alginate and Ce(NO3)3·6H2O by ball milling, and the powder particle size ranges from 1 μm to 50 μm.

[0017] Optionally, in step S2, graphene oxide is also added.

[0018] The present invention also provides a use of the above-mentioned hemostatic powder for rapid hemostasis of traumatic hemorrhage, wherein the hemostatic powder is used for emergency pre-hospital hemostasis of traumatic massive hemorrhage.

[0019] Compared with the prior art, the technical solution of the present invention has at least the following beneficial effects:

[0020] 1) The hemostatic powder prepared by the present invention can make use of the property of sodium alginate to become viscous after absorbing water, concentrate platelets and initially promote blood coagulation; the calcium ions released by the calcium chloride powder after absorbing water can coordinate with sodium alginate to trigger the formation of hydrogel. Furthermore, the calcium ions released by the hemostatic powder of the present invention can activate coagulation factors, and promote the formation of complexes between tissue factors and coagulation factors, form fibrin, enhance platelet embolism, and promote platelets to form stable blood clots.

[0021] 2) Furthermore, based on the high coordination coefficient of cerium ions, the present invention utilizes the coordination effect of cerium ions to cross-link carboxylated graphene oxide and sodium alginate to form a dense network structure, thereby increasing the viscosity and mechanical strength of the hemostatic powder to form a gel after water absorption, making it easier to adhere to the wound surface to resist blood erosion.

[0022] 3) The main raw material of the hemostatic powder of the present invention is derived from natural biological products, which is easily degradable, will not cause a large waste of resources, is environmentally friendly, and the preparation method is simple and easy to control. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is a schematic diagram of the water absorption comparison results in Example 12.

[0024] Figure 2 Schematic diagram of the comparison of water absorption between SA-CC (10:1:1) and SA-CCG (10:1:1:0.3).

[0025] Figure 3 Schematic diagram of the comparison results of stress-strain tests in Example 13.

[0026] Figure 4 This is a schematic diagram of the compression modulus comparison results in Example 13.

[0027] Figure 5 The figure is a schematic diagram of the scanning electron microscopy comparison of SA-CC and SA-CCG in Example 14. Among them, A is the gel formed by SA-CC (10:1:1) magnified 2000 times, B is the gel formed by SA-CC (10:1:1) magnified 500 times, C is the gel formed by SA-CCG (10:1:1:0.3) magnified 2000 times, and D is the gel formed by SA-CCG (10:1:1:0.3) magnified 500 times.

[0028] Figure 6 This is a schematic diagram of the in vitro coagulation effect comparison in Example 15.

[0029] Figure 7 This is a schematic diagram of the cell survival rate comparison after different concentrations of SA-CCG were co-incubated with fibroblasts for 24 hours in Example 16.

[0030] Figure 8 1 is a diagram showing the hemostatic effect of the SA-CCG rat liver injury model in Example 17. A is a schematic diagram of bleeding after liver injury, B is a comparison diagram of hemostasis time, C is a comparison diagram of bleeding volume, and D is a comparison diagram of coagulation at different times.

[0031] Fig. 9The diagram is a diagram of the hemostatic effect of the tail amputation model in SA-CCG rats in Example 18. A is a schematic diagram of bleeding in the tail amputation model, B is a comparison diagram of hemostasis time, C is a comparison diagram of bleeding volume, and D is a comparison diagram of coagulation at different times. DETAILED DESCRIPTION

[0032] The technical solution of the present invention will be described clearly and completely below in conjunction with the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0033] Hemostatic powder uses a large amount of liquid in the bleeding environment as a switch to trigger the hemostatic material to change from a powder state to a gel state. Compared with other existing hemostatic powders, the hemostatic powder prepared by the present invention uses a bimetallic ion crosslinking agent Ca 2+ 、Ce 3+ Cross-linked with sodium alginate to form gel, and Ce 3+ The strong coordination properties of sodium alginate and graphene oxide cross-link to form a hyperbranched network structure, which further improves the viscosity and mechanical properties of the gel and has better clinical application and transformation potential.

[0034] The hemostatic powder prepared by the present invention is innovative in the strategy of rapid gelation to block bleeding sites. It uses a large amount of liquid in the bleeding environment as a switch to trigger a high-viscosity, high-mechanical-strength gel to block blood vessel bleeding, and proposes a "three-step synergistic" strategy: first, by virtue of the property that sodium alginate in the hemostatic powder component absorbs water and becomes viscous, concentrated platelets initially promote coagulation, and build the first "defense line" for hemostasis; secondly, calcium ions released after calcium chloride powder in the hemostatic powder absorbs water can coordinate with sodium alginate on the one hand, triggering the formation of hydrogel; on the other hand, the released calcium ions can start the hemostatic biochemical program in the body, induce platelet activation, thereby promoting rapid coagulation of the wound surface, and further strengthening the "defense line"; finally, based on the "lanthanide contraction" theory and the high coordination coefficient characteristics of cerium ions, carboxylated graphene oxide and sodium alginate, which are important components in the hemostatic powder, are cross-linked through coordination to form a dense network structure, thereby improving the viscosity and mechanical properties of the hemostatic gel and building a solid "defense line" for hemostasis.

[0035] The invention provides a hemostatic powder for rapid hemostasis of traumatic bleeding, comprising sodium alginate, CaCl2 and Ce(NO3)3·6H2O. Optionally, the mass ratio of sodium alginate:CaCl2:Ce(NO3)3·6H2O is (5-20):1:(1-2).

[0036] Furthermore, the present invention also provides a hemostatic powder for rapid hemostasis of traumatic bleeding, comprising: sodium alginate, CaCl2, Ce(NO3)3·6H2O and graphene oxide. Optionally, the mass ratio of sodium alginate: CaCl2: Ce(NO3)3·6H2O: graphene oxide is (5-20): 1: (1-2): (0.1-0.5). Optionally, the mass ratio of sodium alginate: CaCl2: Ce(NO3)3·6H2O: graphene oxide is 10: 1: 1: (0.1-0.5).

[0037] The present invention provides a method for preparing an organic-inorganic hybrid quick hemostatic powder, comprising the following steps:

[0038] (1) Anhydrous calcium chloride (CaCl2) particles are ball-milled into a uniform and fine powder with a powder particle size ranging from 1 μm to 50 μm;

[0039] (2) ball-milling the anhydrous calcium chloride (CaCl2) powder obtained in step (1) with sodium alginate (SA) and cerium nitrate hexahydrate (Ce(NO3)3·6H2O) to obtain (SA-CC), wherein the powder particle size ranges from 1 μm to 50 μm;

[0040] (3) The anhydrous calcium chloride (CaCl2) powder obtained in step (1) is evenly mixed with sodium alginate (SA), cerium nitrate hexahydrate (Ce(NO3)3·6H2O) and graphene oxide (GO) by ball milling to obtain (SA-CCG), and the powder particle size range is 1 μm-50 μm.

[0041] In one embodiment of the present invention, sodium alginate powder, anhydrous calcium chloride particles, and hexahydrate cerium nitrate particles are weighed in a certain proportion and placed in a ball mill.

[0042] In one embodiment of the present invention, the ball milling parameters are controlled as follows: 8 medium balls and 8 small balls at 180 rpm, and the ball milling time is 20 minutes.

[0043] In one embodiment of the present invention, before ball milling, the ball mill is protected by nitrogen for 5 minutes.

[0044] The invention provides an organic-inorganic hybrid rapid hemostatic powder for use in first aid for traumatic massive hemorrhage caused by battlefields or accidental disasters, which can achieve emergency pre-hospital hemostasis.

[0045] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments.

[0046] In the following examples, unless otherwise specified, all reagents used are commercially available reagents; and the detection methods and means described are conventional detection methods and means in the art.

[0047] Example 1

[0048] This embodiment provides a method for preparing anhydrous calcium chloride powder.

[0049] Weigh 1 g of CaCl2 and put it into a ball mill. The milling parameters are 180 rpm, 8 medium balls and 8 small balls, and 20 minutes.

[0050] Example 2

[0051] This example provides a method for preparing SA-C (10:1).

[0052] Sodium alginate powder and anhydrous calcium chloride particles were weighed in a certain mass ratio and placed in a ball mill. The ball milling parameters were controlled to be 180 rpm, 8 medium balls and 8 small balls, and 20 minutes to obtain a uniformly mixed SA-C hemostatic powder.

[0053] The dosage of the raw materials of the present invention is: 100 mg of sodium alginate and 20 mg of anhydrous calcium chloride powder.

[0054] Example 3

[0055] This example provides a method for preparing SA-CC (5:1:1).

[0056] Weigh sodium alginate powder, anhydrous calcium chloride particles, and hexahydrate cerium nitrate particles according to a certain mass ratio and put them into a ball mill. Control the ball milling parameters to 180rpm, 8 medium balls and 8 small balls, and 20 minutes. Then, a uniformly mixed SA-CC hemostatic powder is obtained.

[0057] The dosage of the raw materials of the present invention is: 100 mg of sodium alginate, 20 mg of anhydrous calcium chloride powder, and 26.2 mg of cerium nitrate hexahydrate.

[0058] Example 4

[0059] This example provides a method for preparing SA-CC (10:1:1).

[0060] Weigh sodium alginate powder, anhydrous calcium chloride particles, and hexahydrate cerium nitrate particles according to a certain mass ratio and put them into a ball mill. Control the ball milling parameters to 180rpm, 8 medium balls and 8 small balls, and 20 minutes. Then, a uniformly mixed SA-CC hemostatic powder is obtained.

[0061] The dosage of the raw materials of the present invention is: 100 mg of sodium alginate, 10 mg of anhydrous calcium chloride powder, and 13.1 mg of cerium nitrate hexahydrate.

[0062] Example 5

[0063] This example provides a method for preparing SA-CC (15:1:1).

[0064] Weigh sodium alginate powder, anhydrous calcium chloride particles, and hexahydrate cerium nitrate particles according to a certain mass ratio and put them into a ball mill. Control the ball milling parameters to 180rpm, 8 medium balls and 8 small balls, and 20 minutes. Then, a uniformly mixed SA-CC hemostatic powder is obtained.

[0065] The dosage of the raw materials of the present invention is: 150 mg of sodium alginate, 10 mg of anhydrous calcium chloride powder, and 13.1 mg of cerium nitrate hexahydrate.

[0066] Example 6

[0067] This example provides a method for preparing SA-CC (20:1:1).

[0068] Weigh sodium alginate powder, anhydrous calcium chloride particles, and hexahydrate cerium nitrate particles according to a certain mass ratio and put them into a ball mill. Control the ball milling parameters to 180rpm, 8 medium balls and 8 small balls, and 20 minutes. Then, a uniformly mixed SA-CC hemostatic powder is obtained.

[0069] The dosage of the raw materials of the present invention is: 200 mg of sodium alginate, 10 mg of anhydrous calcium chloride powder, and 13.1 mg of cerium nitrate hexahydrate.

[0070] Example 7

[0071] This example provides a method for preparing SA-CC (15:1:2).

[0072] Weigh sodium alginate powder, anhydrous calcium chloride particles, and hexahydrate cerium nitrate particles according to a certain mass ratio and put them into a ball mill. Control the ball milling parameters to 180rpm, 8 medium balls and 8 small balls, and 20 minutes. Then, a uniformly mixed SA-CC hemostatic powder is obtained.

[0073] The dosage of the raw materials of the present invention is: 150 mg of sodium alginate, 10 mg of anhydrous calcium chloride powder, and 26.2 mg of cerium nitrate hexahydrate.

[0074] Example 8

[0075] This example provides a method for preparing SA-CC (10:1:2).

[0076] Weigh sodium alginate powder, anhydrous calcium chloride particles, and hexahydrate cerium nitrate particles according to a certain mass ratio and put them into a ball mill. Control the ball milling parameters to 180rpm, 8 medium balls and 8 small balls, and 20 minutes. Then, a uniformly mixed SA-CC hemostatic powder is obtained.

[0077] The dosage of the raw materials of the present invention is: 100 mg of sodium alginate, 10 mg of anhydrous calcium chloride powder, and 26.2 mg of cerium nitrate hexahydrate.

[0078] Example 9

[0079] This example provides a method for preparing SA-CCG (10:1:1:0.1).

[0080] Weigh SA-CC powder and graphene oxide according to a certain mass ratio and put them into a ball mill. The ball milling parameters are controlled to be 180rpm, 8 medium balls and 8 small balls, and 20 minutes. Then, a uniformly mixed SA-CCG hemostatic powder is obtained.

[0081] The dosage of the raw materials of the present invention is: 100 mg of sodium alginate, 10 mg of anhydrous calcium chloride powder, 13.1 mg of cerium nitrate hexahydrate, and 1 mg of graphene oxide.

[0082] Example 10

[0083] This example provides a method for preparing SA-CCG (10:1:1:0.3).

[0084] Weigh SA-CC powder and graphene oxide according to a certain mass ratio and put them into a ball mill. The ball milling parameters are controlled to be 180rpm, 8 medium balls and 8 small balls, and 20 minutes. Then, a uniformly mixed SA-CCG hemostatic powder is obtained.

[0085] The dosage of the raw materials of the present invention is: 100 mg of sodium alginate, 10 mg of anhydrous calcium chloride powder, 13.1 mg of cerium nitrate hexahydrate, and 3 mg of graphene oxide.

[0086] Embodiment 11

[0087] This example provides a method for preparing SA-CCG (10:1:1:0.5).

[0088] Weigh SA-CC powder and graphene oxide according to a certain mass ratio and put them into a ball mill. The ball milling parameters are controlled to be 180rpm, 8 medium balls and 8 small balls, and 20 minutes. Then, a uniformly mixed SA-CCG hemostatic powder is obtained.

[0089] The dosage of the raw materials of the present invention is: 100 mg of sodium alginate, 10 mg of anhydrous calcium chloride powder, 13.1 mg of cerium nitrate hexahydrate, and 5 mg of graphene oxide.

[0090] Example 12

[0091] This example provides a comparison of the water absorption measurements of SA-CC and SA-CCG.

[0092] Weigh 0.1 g (m0) of the SA-CC hemostatic powder prepared in Examples 3 to 8, add 10 mL of deionized water, swell for 10 min, centrifuge at 4000 rpm for 5 min, discard the supernatant, and weigh the mass (m1). All tests were repeated three times.

[0093] Water absorption rate W (%) = (m1-m0) / m0×100%, where m0 is the mass before water absorption and m1 is the mass after water absorption.

[0094] Figure 1 This is the water absorption comparison result of this embodiment. Powder 1 in the figure is a raw powder sample prepared by the method of Example 3, powder 2 is a raw powder sample prepared by the method of Example 4, powder 3 is a raw powder sample prepared by the method of Example 5, powder 4 is a raw powder sample prepared by the method of Example 6, powder 5 is a raw powder sample prepared by the method of Example 7, and powder 6 is a raw powder sample prepared by the method of Example 8.

[0095] The results show that the water absorption rate of SA-CC (10:1:1) prepared in Example 4, i.e., the mass ratio of sodium alginate, calcium chloride and cerium nitrate is 10:1:1, is the highest.

[0096] Figure 2 It is the comparison result of water absorption between SA-CC (10:1:1) and SA-CCG (10:1:1:0.3). The results show that the water absorption of SA-CCG is slightly improved compared with that of SA-CC.

[0097] Embodiment 13

[0098] This example provides a comparison of mechanical property measurements of SA-CCG.

[0099] Cut off the lid and bottom of a 5mL centrifuge tube and place it in a 24-well plate. Weigh 25 mg of the SA-CCG hemostatic powder prepared in Examples 9-11 and place them in centrifuge tubes. Add 1 mL of water to form a cylindrical gel. Take it out and place it on a universal testing machine to test the compression performance. The diameter of the gel is 12 mm and the bottom area is 1809.6 mm 2 , the height is precisely measured using a vernier caliper. Enter the gel parameters on the universal testing machine and start the compression test. After the test, the stress-strain curve and compression modulus of the gel are obtained. Each group of samples is measured three times in parallel.

[0100] Figure 3 , Figure 4 It is the comparison result of the mechanical properties of this embodiment. Powder 1 in the figure is the raw powder sample (SA-C) prepared by the method of Example 2, powder 2 is the raw powder sample (SA-CC) prepared by the method of Example 3, powder 3 is the raw powder sample SA-CCG (10:1:1:0.1) prepared by the method of Example 9, powder 4 is the raw powder sample SA-CCG (10:1:1:0.3) prepared by the method of Example 10, and powder 5 is the raw powder sample SA-CCG (10:1:1:0.5) prepared by the method of Example 11.

[0101] The results show that the SA-CCG (10:1:1:0.3) prepared in Example 10, i.e., the one with a mass ratio of sodium alginate, calcium chloride, cerium nitrate, and graphene oxide of 10:1:1:0.3, has the best mechanical properties.

[0102] Embodiment 14

[0103] This example provides the morphological characterization of SA-CC and SA-CCG.

[0104] Weigh 20 mg of the hemostatic powder prepared in Example 4 and Example 10 respectively, place them in 5 mL centrifuge tubes, and add 1 mL of water to form a gel. Place the formed gel sample in a -80°C refrigerator for pre-freezing for 12 hours. Then, cut off the lid of the centrifuge tube, wrap it with a sealing film, and poke a few small holes in the sealing film. After refrigeration, vacuumize the freeze dryer and place the sample in for freeze drying. Take out the freeze-dried sample and cut it open for scanning electron microscopy cross-sectional images.

[0105] Figure 5 The scanning electron microscope results of this embodiment. A (magnified 2000 times) and B (magnified 500 times) are gels formed by a hemostatic powder formula with a mass ratio of sodium alginate, calcium chloride, and cerium nitrate of 10:1:1. Its porous network structure shows that the hemostatic powder has the ability to quickly absorb liquid and transform into gel. C (magnified 2000 times) and D (magnified 500 times) are formulas doped with graphene oxide, in which the mass ratio of sodium alginate, calcium chloride, cerium nitrate, and graphene oxide is 10:1:1:0.3. The crosslinking degree of the gel doped with graphene oxide is increased, which improves the mechanical properties of the gel.

[0106] Embodiment 15

[0107] This example provides a comparison of the in vitro coagulation properties of SA-CC and SA-CCG.

[0108] Prepare blood samples for the experiment. Put the collected blood into an anticoagulation tube and store it in a -24℃ refrigerator. Then, mix 1200μL of anticoagulated blood with 800μL of 0.1mol / L calcium chloride solution (supplement calcium ions to simulate the actual environment of whole blood) to obtain a whole blood sample. Take 50μL of the obtained whole blood sample and place it in a 96-well plate. Then, put 10mg of hemostatic powder with different formulas into the above 96-well plate and start timing. Stop timing at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, and 4 minutes respectively, and add PBS to the well plate to wash away the uncoagulated blood components. When the blood in the well plate completely turns into a clot and PBS cannot wash it away, it is the coagulation time. Use hemostatic powder with a mass ratio of sodium alginate and calcium chloride of 10:1 as a positive control. Use a whole blood sample as a negative control.

[0109] Figure 6 It is the in vitro coagulation performance comparison result of this embodiment. The results show that within 4 minutes, the whole blood sample (blood alone) as a control group cannot coagulate on its own. The pure sodium alginate powder (SA) cannot cross-link with the calcium ions in the whole blood sample to form a gel, and it cannot effectively coagulate the blood. The reason may be that the solubility of sodium alginate in water is poor (sodium alginate powder dissolves slowly in water and needs to be stirred for several hours before it can be completely dissolved to form a viscous liquid). The small amount of dissolved sodium alginate forms a gel with the calcium ions in the whole blood, which will form a barrier between the undissolved sodium alginate and the liquid components, hindering the further dissolution and cross-linking of the sodium alginate powder. However, the mixed powder of sodium alginate and calcium chloride (SA-C) can quickly absorb the liquid components in the blood, form a gel, and coagulate the blood, and its coagulation time is shorter than 1 minute (shown by the white dotted circle). The double cross-linking agent mixed hemostatic powder (SA-CC) made of sodium alginate, calcium chloride, and cerium nitrate powder also has a good coagulation effect. It can cross-link the blood to form a gel within 1 minute (indicated by the white dotted circle), thereby achieving the coagulation effect. The hemostatic powder (SA-CCG) prepared by mixing sodium alginate, calcium chloride, cerium nitrate, and graphene oxide has the best hemostatic effect. It can cross-link the blood to form a gel within half a minute (indicated by the white dotted circle), proving the excellent in vitro coagulation performance of SA-CCG.

[0110] Example 16

[0111] This example provides a cytotoxicity test of SA-CCG.

[0112] The SA-CCG prepared in Example 10 was immersed in a cell culture medium for 24 hours, and then co-incubated with vascular endothelial cells L929 for 24 hours. The cell survival rate was determined by the CCK8 method.

[0113] Figure 7 The results of the cytotoxicity test in this example show that high concentrations of SA-CCG hemostatic powder will not produce significant toxicity to normal cells, indicating that it has good cell compatibility and illustrating the safety of SA-CCG.

[0114] Embodiment 17

[0115] This example provides an in vivo SA-CCG rat liver injury model.

[0116] After anesthesia, the rat was fixed in supine position, the left liver lobe was exposed, and a 5 mm long and 3 mm deep incision was made on the liver lobe with a scalpel. SA-CCG prepared in Example 10 was sprinkled on the incision site, and the bleeding state was observed. The time difference from the start of bleeding to the stop of blood oozing from the wound was recorded as the hemostasis time; at the same time, the mass difference between the filter disc and the hemostatic powder before and after the experiment was recorded as the blood loss.

[0117] Figure 8 This is the hemostatic effect of the liver injury model of this example. Figure 8 A is a schematic diagram of hemorrhage in the liver injury model. The results showed that the untreated control group had a long bleeding time and a large amount of bleeding, and the hemostasis time reached 266s ( Figure 8 B), the amount of bleeding was 283mg ( Figure 8 C); When SA-CCG is applied to a wound, the powder immediately turns into a gel, creating a tight barrier to inhibit wound bleeding ( Figure 8 D), its coagulation time is only 97s ( Figure 8 B), the amount of bleeding decreased to 179mg ( Figure 8 C), proving that SACC-GO has excellent hemostatic ability.

[0118] Embodiment 18

[0119] This example provides an in vivo SA-CCG rat tail docking model.

[0120] After anesthesia, the rats were fixed in supine position, 50% of the tail length was cut off, and the SA-CCG prepared in Example 10 was sprinkled on the incision site to observe the bleeding state. The time difference from the start of bleeding to the stop of blood oozing out of the wound was recorded as the hemostasis time; at the same time, the mass difference between the filter disc and the hemostatic powder before and after the experiment was recorded as the blood loss.

[0121] Fig. 9 This is the hemostatic effect of the tail amputation model of this embodiment. Fig. 9 A is a schematic diagram of bleeding in the tail-cut model. The results showed that the control group had a long bleeding time and a large amount of bleeding, while the material group (SA-CCG) showed significant differences. The control group's hemostasis time was about 732s ( Fig. 9 B), and the amount of bleeding was as high as 1486mg ( Fig. 9 In contrast, in the SACC-GO group, when the powder was deposited on the bleeding site, the powder quickly absorbed blood and formed a gel thrombus, and as time went on, the gel adhered tightly to the wound surface and no blood flowed out, indicating that the bleeding was effectively controlled ( Fig. 9 D), and the coagulation time is 311s ( Fig. 9 B), blood loss was significantly reduced to 352mg ( Fig. 9 C), further proving its excellent hemostatic ability.

[0122] In summary, the present invention starts from the research and development of a low-cost, easy-to-use rapid hemostatic material, uses a large amount of liquid in the bleeding environment as a switch to activate the transformation of hemostatic powder to hemostatic hydrogel, and then uses coordination chemical cross-linking to improve the viscosity and mechanical strength of the hydrogel, and finally achieves the purpose of rapid hemostasis through component regulation and ratio optimization. The present invention can be applied to pre-hospital rapid hemostasis, and provides a new idea for the research and development of rapid hemostatic materials for battlefield or accidental disaster trauma first aid.

[0123] Although the content of the present invention has been described in detail through the above preferred embodiments, it should be appreciated that the above description should not be considered as a limitation of the present invention. After reading the above content, it will be apparent to those skilled in the art that various modifications and substitutions of the present invention will occur. Therefore, the protection scope of the present invention should be limited by the appended claims.

Claims

1. A hemostatic powder for rapid hemostasis of traumatic bleeding, characterized in that: The hemostatic powder comprises sodium alginate, CaCl2 and Ce(NO3)3·6H2O.

2. The hemostatic powder for rapid hemostasis of traumatic bleeding according to claim 1, characterized in that: The mass ratio of sodium alginate: CaCl2: Ce(NO3)3·6H2O is (5-20): 1: (1-2).

3. The hemostatic powder for rapid hemostasis of traumatic hemorrhage according to claim 2, characterized in that: The mass ratio of sodium alginate: CaCl2: Ce(NO3)3·6H2O is 10:1:

1.

4. The hemostatic powder for rapid hemostasis of traumatic hemorrhage according to claim 1, characterized in that: The hemostatic powder further comprises: graphene oxide.

5. The hemostatic powder for rapid hemostasis of traumatic hemorrhage according to claim 4, characterized in that: The mass ratio of sodium alginate: CaCl2: Ce(NO3)3·6H2O: graphene oxide is (5-20): 1: (1-2): (0.1-0.5).

6. The hemostatic powder for rapid hemostasis of traumatic hemorrhage according to claim 5, characterized in that: The mass ratio of sodium alginate: CaCl2: Ce(NO3)3·6H2O: graphene oxide is 10:1:1: (0.1-0.5).

7. The hemostatic powder for rapid hemostasis of traumatic hemorrhage according to claim 6, characterized in that: The mass ratio of sodium alginate:CaCl2:Ce(NO3)3·6H2O:graphene oxide is 10:1:1:0.

3.

8. A method for preparing the hemostatic powder for rapid hemostasis of traumatic hemorrhage according to any one of claims 1 to 7, characterized in that: The following steps are involved: Step S1, grinding anhydrous calcium chloride particles into anhydrous calcium chloride powder, the powder particle size range is 1 μm-50 μm; Step S2, the anhydrous calcium chloride powder is evenly mixed with sodium alginate and Ce(NO3)3·6H2O by ball milling, and the powder particle size ranges from 1 μm to 50 μm.

9. The method for preparing the hemostatic powder for rapid hemostasis of traumatic hemorrhage according to claim 8, characterized in that: In the step S2, graphene oxide is also added.

10. Use of the hemostatic powder for rapid hemostasis of traumatic bleeding according to any one of claims 1 to 7, characterized in that: The hemostatic powder is used for emergency pre-hospital hemostasis of traumatic massive hemorrhage.